Lnterleukin-27 activates natural killer cells and suppresses NK-resistant head and neck squamous cell carcinoma through inducing antibody-dependent cellular cytotoxicity

Cancer Research

Volumn 69, Issue 6, 2009, Pages 2523-2530

  Matsui, Masahiro ^a,b   Kishida, Tsunao ^b   Nakano, Hiroshi ^a   Yoshimoto, Koichiro ^a,b   Shin Ya, Masaharu ^b   Shimada, Taketoshi ^a   Nakai, Shigeru ^a   Imanishi, Jiro ^b   Yoshimoto, Takayuki ^c   Hisa, Yasuo ^a   Mazda, Osam ^b  

^a Department of Otorhinolaryngology Head and Keck Surgery ^*  (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CYTOKINE; GRANZYME B; IMMUNOGLOBULIN G; INTERLEUKIN 27; PLASMID VECTOR; STAT1 PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR T BET; INTERLEUKIN 17;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD SAMPLING; CANCER GENE THERAPY; CANCER INHIBITION; CELL ACTIVATION; CELL MEDIATED CYTOTOXICITY; CELL VIABILITY; CONTROLLED STUDY; FEMALE; HEAD AND NECK CARCINOMA; IMMUNOGLOBULIN BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA; SURVIVAL; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; C3H MOUSE; GENETIC TRANSFECTION; GENETICS; HEAD AND NECK TUMOR; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; INTERLEUKIN-17; KILLER CELLS, NATURAL; MICE; MICE, INBRED C3H; TRANSFECTION;

EID: 65549088112     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2793     Document Type: Article

References (50)

1. Pfanz S. Hibbert L. Maltson J. el al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol 2004;72:2225-31.
2. Pflanz S, Tiimans JC. Cheung J. et al. IL-27, a heterodimeric cytokine composed of EB13 and p2S protein, induces proliferation of naive CD4(+) T cells. Immunity 2002:16:779-90.
3. Takeda A, Hamano S. Yamanaka A, et al. Cutting edge: role of IL-27/WSX-1 signaling for induction of T- bet through activation of STAT1 during initial Th1 commitment, Immunol 2003;170:4886-90."
4. Kamiya S, Owaki T, Morishima N. et al. An indispensable role for STAT1 in IL-27-induced T-bet expression but not proliferation of naive CD4+ T cells. J Immunol 2004:173:3871-7.
5. Hibbert L. Manz S, De Waal Malefyt R. Kastelein RA. IL-27 and ITN-α signal via Stat1 and Stat3 and induce T-bet and IL-12Rβ2 in naive T cells, J Interferon Cytokine Res 2003;23:513-22.
6. Lucas S. Ghilardi N. Li J. de Sauvage FJ. IL-27 regulates 1L-12 responsiveness of naive CD4+ T cells through Stat 1-dependent and -independent mechanisms. Proc Natl Acad Sci USA 2003:100:15047-52.
7. Yoshimura T. Takeda A Hamano S. et al. Two-sided roles of IL-27: induction of Th1 differentiation on naive CÜ4+ T cells versus suppression of proinflammatory cytokine production including lL-23-induced 1L-17 on activated CD4+ T cells partially through STAT3-dependent mechanism, J Immunol 2006:177:5377-85.
8. Yoshimoto T. Yoshimolo T. Yasuda K. Mizuguchi J, Nakanishi K. IL-27 suppresses Th2 cell development and novel therapeutic way for Th2-medialed allergic inflammation, J Immunol 2007:179:4415-23.
9. Neufert C, Becker C. Wintz S. el al. IL-27 controls the development of inducible regulators T cells and Thl7 cells via differential effects on STAT 1. Eur J Immunol 2007;37:1809-16.
10. Morishima N. Owaki T, Asakawa M, et al. Augmentation of effector CDS+ T cell generation with enhancedgranzyme B expression by IL-27. J Immunol 2005:175: 1686-93.
11. Hisada M. Kamiya S, Fujita K, et al. Potent antitumor activity of inlerleukin-27. Cancer Res 2004; 64:1152-6.
12. Salcedo R, Stauffer JK, Lincoln E, et al. IL-27 mediates static murine neuroblastoma tumors: role for CD8+ T cells. J Immunol 2004:173:7170-82.
13. Larousserie F, Charcot P. Bardel E, Froger J. Kastelein RA. Deverqne O. Differential effects of IL-27 on human B cell subsets. J Immunol 2006;176:5890-7.
14. Yoshimoto T, Okada K, Morishima N. et al. Induction 2004;173:2479-85.
15. Humano S. Himeno K. Miyazaki Y. et al. WSX-1 is by regulation of proinflammatory cytokine production. Immunity 2003;19:657-67.
16. Yamanaka A. Hamano S, Miyazaki Y, et al. Hyper- production of proinflammatory cytokines by WSX-1- deficient NKT cells in concanavalinA-induced hepatitis. J Immunol 2004:172:3590-6.
17. Wirtz S. Tubbe I, Galle PR. et al. Protection from lethal septic peritonitis by neutralizing the biological function of interleukin 27. J Exp Med 2006:203:1875-81.
18. Wang S, Miyazuki Y, Shinozaki Y, et al. Augmentation of antigen-presenting and Thl-promoting functions of dendritic cells by WSX-1 (1L-27R) deficiency. J Immunol 2007:179:6421-8.
19. Artis D. Villarino A. Silverman M. el al. The IL-27 receptor (WSX-1) is an inhibitor of innate and adaptive elements of type2 immunity. J Immunol 2004;173:5626-34,
20. Nakano H. Kishida T, Asada H. et al. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma. J Gene Med 2006;8:90-9.
21. Itokawa Y, Mazda O, Ueda Y, et al. IL-12 Generic Administration Suppressed Metastatic Liver Tumor Unsusceptible to CTL. Biochem Biophys Res Commun 2004:314:1072-9.
22. Villarino AV. Larkin III J, Saris CJM, et al. Positive and Negative Regulation of the IL-27 Receptor during Lymphoid Cell Activation. J Immunol 2005;174:7684-91.
23. Batten M. Ghilardi N. The biology and therapeutic potential of interleukin 27. [ Mol Med 2007:85:661-72.
24. Yoshida H, Hamano S, Senaldi G, et al. WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity 2001;15:569-78.
25. Villarino A, Hibbert L, Lieberman L, et al. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 2003:19:645-55.
26. Pearl JE. Khader SA. Solache A, et al. IL-27 signal- bacteria-infected mice. J Immunol 2004;173:7490-6.
27. Holscher C, Holscher A, Ruckerl D. et al. The IL-27 receptor chain WSX-1 differentially regulates antibacterial immunity and survival during experimental tuberculosis. J Immunol 2005;174:3534-44.
28. Rosas LE. Saloskar AA Roth KM, et al. Inlerleukin-27R(WSX-l/T-cell cytokine receptor) gene-deficient mice display enhanced resistance to Leishmania donovani infection but develop severe liver immunopathology. Am J Pathol 2006;168:158-69.
29. Chen Q, Ghilardi N, Wang H, et al. Development of Th1-type immune responses requires the type I cytokine receptor TCCR. Nature 2000:407:916-20.
30. Nieuwenhuis EE, Neurath MF, Corazza N, et al. Disruption of T helper 2-immune responsesin Epstein-Rarr virus-induced gene 3-deficient mice. Proc Natl Acad Sci USA 2002:99:16951-6.
31. Chiyo M, Shimozalo O, Yu L. et al. Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals, Int J Cancer 2005:115:137-12.
32. Shimizu M, Shimamura M. Owaki T, et al. Antiangiogenic and antitumor activities of IL-27. J Immunol 2006; 176:7317-24.
33. Oniki S, Nagai H. Horikawa T, et al. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res 2006;66:6395-404.
34. Sung MW. Yasumura S, Johnson JT. Van Dongen CA. Whiteside TL. Natural killer (NK) cells as effectors of antibody-dependent cytotoxicity with chimeric anti-bodies reactive with human squamous-cell carcinomas of the head and neck, Int J Cancer 1995:61:864-72.
35. Carson WE, Parihar R. Lindemann MJ, et al. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol 2001;31:3016-25.
36. Golay J, Manganini M. Facchinetti V, el al. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic R cells is stimulated strongly by interleukin-2. Haematologica 2003;88:1002-12.
37. Lopes de Menezes DE, Denis-Mize K, Tang Y, et al, of retuximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma. J Immunother 2007;30:64-74.
38. Parihar R. Dierksheide J, Hu Y, Carson WE, IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J Clin Invest 2002;110:983-92.
39. Moga E, Alvarez E, Canto E, el al. NK cells stimuloated with 1L-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma. Exp Hematol 2008:36:69-77.
40. Roda JM. Parihar R. Lehman A Mani A. Tridandapani S. Carson WE III. Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J Immunol 2006;177:120-9.
41. Cluck WL, Hurst I), Yuen A. et al. Phase I studies of interleukin (lL)-2 and rituximab in B-cell non-Hodgkins lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 2004;10:2253-64.
42. Eisenbeis CF. Grainger A. Fischer B, et al. Combination immunotherapy of B-cell non-Hodgkins lymphoma with rituximab and interleukin-2: a preclinical and phase 1 study. Clin Cancer Res 2004:10:6101-10.
43. Shimizu S. Sugiyama N. Masutani K. et al. Th2-type immune deviations in MRL/lpr mice deficient for IL-27 receptor (WSX-1). J Immunol 2005;175: 7185-92.
44. Miyazaki Y. Inoue H, Matsumura M. et al. Exacerbation of experimental allergic asthma by augmented Th2 responses in WSX-l-deficient mice. J Immunol 2005:175: 2401-7.
45. Li S, Zhang X, Xia X, Regression of tumor growth and induction of long-term antitumor memory by interleukin 12 electro-gene therapy. J Natl Cancer Inst 2002:94: 762-8.
46. Hanna E. Zhang X. Woodlis J. et al. Intramuscular electroporation delivery of IL-12 gene for treatment of squamous cell carcinoma located at distant site. Cancer Gene Ther 2001;8:151-7.
47. Motzer RJ. Rakhit A Schwartz LH. et al. Phase 1 trial of subcutaneous recombinant human interleukin-12 in Cancer Res 1998:4:1183-91.
48. Chikano S, Sawada K. Shimoyama T, et al. 1L-18 and IL-12 induce intestinal inflammation and fatty liver in mice in an IFN-γ dependent manner. Gut 2000:47:779-86.
49. Colombo MP. Trinchieri G. interleukin-12 in anti- Factor Rev 2002;13:155-68.
50. van Herpen CM. van der Laak JA, de Vries IJ, et al. Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor. Clin Cancer Res 2005;11: 1899-909.